Analysts Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) PT at $18.83

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been assigned an average rating of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $18.83.

Several equities analysts have recently commented on ALXO shares. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of ALX Oncology in a research report on Wednesday, April 10th. Stifel Nicolaus reaffirmed a “hold” rating and set a $14.00 price target (up from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research report on Friday, April 12th.

ALX Oncology Price Performance

Shares of NASDAQ ALXO opened at $15.50 on Wednesday. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.05. The business’s 50 day moving average price is $13.60 and its two-hundred day moving average price is $12.15. The company has a market cap of $775 million, a PE ratio of -4.13 and a beta of 1.58. ALX Oncology has a twelve month low of $3.94 and a twelve month high of $17.42.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). On average, analysts predict that ALX Oncology will post -3.33 EPS for the current year.

Insider Activity

In related news, insider Jaume Pons sold 20,000 shares of the stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $11.15, for a total transaction of $223,000.00. Following the sale, the insider now owns 628,359 shares in the company, valued at approximately $7,006,202.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Jason Lettmann bought 4,400 shares of the firm’s stock in a transaction on Thursday, March 14th. The shares were purchased at an average price of $11.31 per share, with a total value of $49,764.00. Following the completion of the purchase, the chief executive officer now owns 171,620 shares in the company, valued at approximately $1,941,022.20. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Jaume Pons sold 20,000 shares of the stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $11.15, for a total value of $223,000.00. Following the completion of the transaction, the insider now owns 628,359 shares of the company’s stock, valued at $7,006,202.85. The disclosure for this sale can be found here. Corporate insiders own 50.30% of the company’s stock.

Hedge Funds Weigh In On ALX Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of ALXO. Vestal Point Capital LP bought a new stake in shares of ALX Oncology during the fourth quarter worth about $24,643,000. TD Asset Management Inc acquired a new stake in ALX Oncology during the 4th quarter worth approximately $1,048,000. Dynamic Technology Lab Private Ltd bought a new stake in ALX Oncology during the 4th quarter worth approximately $215,000. Jump Financial LLC acquired a new position in ALX Oncology in the 4th quarter valued at approximately $371,000. Finally, abrdn plc bought a new position in shares of ALX Oncology during the fourth quarter valued at $986,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.